» Articles » PMID: 34471517

What's New in Pulmonary Hypertension Clinical Research: Lessons from the Best Abstracts at the 2020 American Thoracic Society International Conference

Overview
Journal Pulm Circ
Publisher Wiley
Specialty Pulmonary Medicine
Date 2021 Sep 2
PMID 34471517
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

In this conference paper, we review the 2020 American Thoracic Society International Conference session titled, "What's New in Pulmonary Hypertension Clinical Research: Lessons from the Best Abstracts". This virtual mini-symposium took place on 21 October 2020, in lieu of the annual in-person ATS International Conference which was cancelled due to the COVID-19 pandemic. Seven clinical research abstracts were selected for presentation in the session, which encompassed five major themes: (1) standardizing diagnosis and management of pulmonary hypertension, (2) improving risk assessment in pulmonary arterial hypertension, (3) evaluating biomarkers of disease activity, (4) understanding metabolic dysregulation across the spectrum of pulmonary hypertension, and (5) advancing knowledge in chronic thromboembolic pulmonary hypertension. Focusing on these five thematic contexts, we review the current state of knowledge, summarize presented research abstracts, appraise their significance and limitations, and then discuss relevant future directions in pulmonary hypertension clinical research.

Citing Articles

Progression of pulmonary arterial hypertension: A study in model.

Cahyono A, Irwanto , Rahman M, Widjiati W Open Vet J. 2025; 14(12):3498-3504.

PMID: 39927369 PMC: 11799619. DOI: 10.5455/OVJ.2024.v14.i12.33.


Extrapulmonary manifestations of pulmonary arterial hypertension.

Singh N, Al-Naamani N, Brown M, Long G, Thenappan T, Umar S Expert Rev Respir Med. 2024; 18(3-4):189-205.

PMID: 38801029 PMC: 11713041. DOI: 10.1080/17476348.2024.2361037.


Acid ceramidase gene therapy ameliorates pulmonary arterial hypertension with right heart dysfunction.

Katz M, Hadas Y, Vincek A, Freage-Kahn L, Shtraizent N, Madjarov J Respir Res. 2023; 24(1):197.

PMID: 37568148 PMC: 10416391. DOI: 10.1186/s12931-023-02487-2.

References
1.
Scott J, Garnett C, Kanwar M, Stockbridge N, Benza R . Enrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical Trials. Am J Respir Crit Care Med. 2020; 203(6):726-736. PMC: 7958501. DOI: 10.1164/rccm.202002-0357OC. View

2.
Hemnes A, Rothman A, Swift A, Zisman L . Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension. Pulm Circ. 2020; 10(4):2045894020957234. PMC: 7682212. DOI: 10.1177/2045894020957234. View

3.
Galie N, Jansa P, Pulido T, Channick R, Delcroix M, Ghofrani H . SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. Eur Heart J. 2017; 38(15):1147-1155. PMC: 5400052. DOI: 10.1093/eurheartj/ehx025. View

4.
Lewis G, Ngo D, Hemnes A, Farrell L, Domos C, Pappagianopoulos P . Metabolic Profiling of Right Ventricular-Pulmonary Vascular Function Reveals Circulating Biomarkers of Pulmonary Hypertension. J Am Coll Cardiol. 2016; 67(2):174-189. PMC: 4962613. DOI: 10.1016/j.jacc.2015.10.072. View

5.
Boucly A, Weatherald J, Savale L, Jais X, Cottin V, Prevot G . Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017; 50(2). DOI: 10.1183/13993003.00889-2017. View